Stephen Hill - Histogen VP Controller
| HSTO Stock | USD 0.02 0.01 25.65% |
Insider
Stephen Hill is VP Controller of Histogen
| Address | 10655 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 858 526 3100 |
| Web | https://www.histogen.com |
Stephen Hill Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Hill against Histogen stock is an integral part of due diligence when investing in Histogen. Stephen Hill insider activity provides valuable insight into whether Histogen is net buyers or sellers over its current business cycle. Note, Histogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Histogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Hill over two months ago Acquisition by Stephen Hill of 85000 shares of Lyell Immunopharma at 1.87 subject to Rule 16b-3 | ||
Stephen Hill over three months ago Acquisition by Stephen Hill of 700000 shares of Lyell Immunopharma at 1.87 subject to Rule 16b-3 | ||
Stephen Hill over six months ago Acquisition by Stephen Hill of 40000 shares of Lyell Immunopharma subject to Rule 16b-3 | ||
Stephen Hill over a year ago Acquisition by Stephen Hill of 500000 shares of Lyell Immunopharma subject to Rule 16b-3 |
Histogen Management Efficiency
The company has return on total asset (ROA) of (0.5381) % which means that it has lost $0.5381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1989) %, meaning that it created substantial loss on money invested by shareholders. Histogen's management efficiency ratios could be used to measure how well Histogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.67. In addition to that, Return On Capital Employed is likely to drop to -0.72. At this time, Histogen's Total Assets are very stable compared to the past year. As of the 27th of November 2024, Non Current Assets Total is likely to grow to about 6.8 M, while Total Current Assets are likely to drop about 11.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| James JD | Eliem Therapeutics | 58 | |
| Lori CPA | Lumos Pharma | 40 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Bradley JD | Lumos Pharma | 45 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| David MBA | Seres Therapeutics | 63 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Susan MS | Eliem Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 |
Histogen Leadership Team
Elected by the shareholders, the Histogen's board of directors comprises two types of representatives: Histogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Histogen. The board's role is to monitor Histogen's management team and ensure that shareholders' interests are well served. Histogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Histogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Hill, VP Controller | ||
| Steven Mento, Interim Chairman | ||
| Thomas Hubka, Director Sec | ||
| Gail Naughton, Founder Advisor | ||
| Susan Knudson, CEO, President |
Histogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Histogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (705.00) % | ||||
| Current Valuation | (4.49 M) | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 2.85 % | ||||
| Number Of Shares Shorted | 67.03 K | ||||
| Price To Book | 0.02 X | ||||
| Price To Sales | 4.50 X | ||||
| Revenue | 19 K |
Pair Trading with Histogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Histogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Histogen will appreciate offsetting losses from the drop in the long position's value.Moving against Histogen Stock
The ability to find closely correlated positions to Histogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Histogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Histogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Histogen to buy it.
The correlation of Histogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Histogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Histogen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Histogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Histogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share 0.004 | Return On Assets (0.54) | Return On Equity (1.20) |
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.